Achillion Pharmaceuticals, Inc. announced that Joel Barrish, Ph.D., has been named the company's Chief Scientific Officer (CSO) and Executive Vice President, effective January 4, 2016. Dr. Barrish joins Achillion with more than 30 years of experience in the pharmaceutical industry. For the last five years, Dr. Barrish was Vice President and Head of Discovery Chemistry at Bristol-Myers Squibb.
Achillion Pharmaceuticals, Inc.
Equities
US00448Q2012
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+9.71% | 115B | |
+13.19% | 107B | |
-13.28% | 22.31B | |
-3.44% | 21.6B | |
-5.29% | 18.23B | |
-38.57% | 17.62B | |
+8.09% | 14.26B | |
+34.46% | 12.37B | |
-26.74% | 8.28B |